The US Food and Drug Administration (FDA) has approved an investigational new drug (IND) application from Aclaris ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight 2025” report provides comprehensive insights about 150+ ...

Keymed Biosciences Inc. (HKEX: 02162) ("Keymed" or the "Company") today announced CM518D1, a CDH17-targeted antibody-drug conjugate (ADC) developed by Keymed, received Investigational New Drug (IND) ...

Tocilizumab has emerged as a key treatment for rheumatoid arthritis, showing efficacy, safety, and potential cardiovascular ...

AbolerIS Pharma ("AbolerIS"), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering from autoimmune and inflammatory diseases, today announced the formation ...

Indian pharma researchers are now focusing on monoclonal antibodies to treat malaria ... innovation, and collective action. With over a 69% decline in malaria cases and deaths between 2017 and 2023, ...

ImCheck Announces Oral Presentation of Updated ICT01 Efficacy Data in First-line AML at the ASCO Annual Meeting 2025 ...

Fintel reports that on April 21, 2025, William Blair initiated coverage of Xencor (NasdaqGM:XNCR) with a Outperform ...

Key treatments for Alzheimer’s, rare cancers, and infectious diseases are under review, with new vaccines and therapies like ...

CM518D1 delivers cytotoxic payloads precisely to tumor cells by a CDH17-specific monoclonal antibody ... (e.g., diverse mechanisms of action), hydrophilic linkers (optimized for stability and drug ...